We use cookies for a better user experience. Read our Privacy Policy

I Agree

Exosome Technologies Market

Exosome Technologies Market (Exosome Type: Loaded Cargo and Non-cargo; Cell Source: HEK293, MSCs, Platelets, Erythrocytes, Natural Killer Cells [NKs], and Others; Indication: Therapeutics and Diagnostics; and End User: Healthcare Providers, Pharmaceutical & Biotechnology Companies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Use of EV-Viral Interplay for Development of Antiviral Drugs for Evolving Coronavirus Strains

The outbreak of severe acute respiratory syndrome β-coronavirus 2 (SARS-CoV-2) has led to a potential long-lasting global health crisis. Thus, extracellular vesicles (EVs) are emerging as a possible solution for improving lung immunity. Companies in the exosome technologies market are increasing their research for conducting the pathogenesis of various lung diseases and viral infections in order to keep economies running during the COVID-19 outbreak.

New coronavirus strains are creating revenue opportunities for companies in the exosome technologies market, as EVs share structural similarities to viruses. Such an EV-viral interplay holds promising potentials for the development of antiviral drugs and vaccine development. Mesenchymal stem cell-derived EVs are being investigated for the treatment of the novel infection.

exosome technologies market segmentation

To know the scope of our report Get a Sample on Exosome Technologies Market

Appropriate Combination of Several Methods Help Improve Limitations of Exosomes

Compared to synthetic carriers such as nanoparticles and liposomes, the heterogeneity and endogeneity of exosomes demonstrate unique advantages in disease diagnosis and treatment. However, storage stability, low purity, and weak targeting of exosomes are limiting its clinical applications. Hence, companies in the exosome technologies market are increasing their R&D to establish the appropriate combination of several methods to extract and purify exosomes to effectively improve over its limitations.

The exosome technologies market is projected to expand at an astonishing CAGR of 24.2% during the assessment period. There is a need to optimize and improvise the exosome loading capacity and methods for enhancing targeting drugs. Companies are increasing efforts to conduct all-round and multi-field researches to analyze the biological functions of exosomes.

Get a glimpse of the in-depth analysis through our Report Brochure

Transdermal Delivery of ASC-Exosomes Facilitates Skin Brightening Through Cosmeceuticals

The cellular intelligence communication is gaining prominence in the field of cosmetics. Exosomes derived from human adipose tissue-derived mesenchymal stem/stromal cells (ASC-exosomes) are being investigated for minimizing skin pigmentation. As such, there is a need to improve the transdermal delivery of ASC-exosomes to enable skin brightening through cosmeceuticals in the exosome technologies market.

There is a high prevalence of individuals suffering from hyperpigmentation or hypermelanosis, which is a skin disorder resulting in excessive accumulation of melanin in the skin leaving the skin aesthetically undesirable. Such skin disorders are acting as a key driver for the exosome technologies market. Exosomes derived from mesenchymal stem/stromal cell (MSC) cultures are a promising next-generation cell-free therapeutic option.

Exosomes Regulate CVD Progression via Exchange of Signal Molecules

Exosomes, also known as extracellular vesicles with a lipid bilayer membrane of endosomal origin have become the focus of a large body of research in cardiovascular diseases (CVD) for companies in the exosome technologies market. These EVs serve as carriers for signal molecules responsible for intracellular and inter-organ communication underlying CVD pathophysiology. Moreover, they help to overcome limitations of the stem cell therapy, since exosomes released by progenitor cells are bioactive and act as key mediators for the stem cell therapy of CVD.

Exosomes play a critical role in cardiovascular pathophysiology, as they help to regulate CVD progression via transport and exchange of signal molecules. For instance, exosomes released by cardiac fibroblasts rescue cardiomyocytes from ischemia-reperfusion injury. 

Exosomes Possess Huge Potential in Field of Cancer Immunotherapy

Cell-derived nanovesicles also known as exosomes have the potential to increase clinical outcomes in cancer immunotherapy, owing to their advantageous immunogenicity and molecular transfer function. Companies in the exosome technologies market are adopting proprietary manufacturing platforms to develop EVs that help to regulate immune responses. They are boosting their production capabilities to develop exosomes that are derived from tumor cells and immune cells, which exhibit unique composition profiles that are directly linked with anti-cancer immunotherapy.

Exosomes hold promising potentials to deliver their cargoes to targeted cells and influence the phenotype and immune-regulation functions of targeted cells. Thus, companies in the exosome technologies market are gaining awareness that exosomes have huge potential in the field of cancer immunotherapy.

exosome technologies market infographic

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The ever-evolving COVID-19 strains have plunged pharmaceutical and biotech companies to accelerate vaccine and antiviral therapeutics to capitalize on incremental opportunities. The exosome technologies market is projected to surpass US$ 300 Mn by the end of 2031. However, secretion mechanism and fusion mechanism of exosomes are still unclear. Hence, companies should conduct all-round multi-field researches to analyze its biological functions and lay the foundation for subsequent clinical testing, pharmacokinetics, and toxicology research to enable targeted drug delivery in patients. They should develop exosomes that can be used to produce effective cancer vaccines and targeted antigens.

Exosome Technologies Market: Overview

  • This report analyzes the current scenario and future prospects of the global exosome technologies market. Rise in prevalence of chronic diseases, increase in awareness about exosome technologies, and government initiatives are projected to boost the growth of the global exosome technologies market.
  • The report includes an elaborate executive summary, which provides a snapshot of various segments of the global exosome technologies market. It also provides information and data analysis of the exosome technologies market about segments based on exosome type, cell source, indication, end user, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that affect the global exosome technologies market
  • The report includes company profiles, which provide information about their business, product portfolios, and competition landscape in the global exosome technologies market
  • The report on the exosome technologies market offers market attractiveness analysis of regions and segments
  • The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global exosome technologies market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global exosome technologies market.

Exosome Technologies Market: Key Segments

  • In terms of exosome type, the global exosome technologies market has been classified into loaded cargo and non-cargo. The loaded cargo segment has been split into peptide, siRNA, mRNA, miRNA, protein, chemical, and others. The loaded cargo segment accounted for major share of the market in 2020, and the trend is anticipated to continue during the forecast period. Increase in specificity of exosome cargo in relation to the cell of origin and surge in the number of applications of loaded cargo are expected to augment the segment.
  • Based on cell source, the global exosome technologies market has been categorized into HEK293, MSCs, platelets, erythrocytes, natural killer cells (NKs), and others. The MSCs segment dominated the market in 2020. Exosomes derived from MSCs have both self-renewal capabilities and differentiation potentials. It can be derived from a range of tissues and body fluids, such as adipose tissue, bone marrow (BM), dental pulp, synovial fluid (SF), amniotic fluid (AF), placenta (PL), umbilical cord (UC), umbilical cord blood (UCB).
  • In terms of indication, the global exosome technologies market has been bifurcated into therapeutics and diagnostics. Promising future of exosomes in therapeutic applications is likely to drive the therapeutics segment.
  • Based on end user, the global exosome technologies market has been divided into healthcare providers, pharmaceutical & biotechnology companies, and others. The healthcare providers segment accounted for major share of the market. Increase in geriatric population with various diseases is projected to propel the segment.
  • Market size and forecast for each of these segments have been provided from 2015 to 2031. The CAGR of respective segments has also been provided from 2021 to 2031, considering 2020 as the base year.

Exosome Technologies Market: Regional Outlook

  • In terms of region, the global exosome technologies market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.
  • The exosome technologies market report provides size and forecast for each region and country/sub-region from 2015 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The exosome technologies market study also covers the competitive scenario in these regions.

Companies Covered in Exosome Technologies Market Report

  • Key players in the global exosome technologies market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the exosome technologies market report are
    • Aegle Therapeutics
    • Anjarium Biosciences
    • Aruna Biomedical
    • Carmine Therapeutics
    • Evox Therapeutics
    • Exosome Diagnostics, Inc.
    • ExonanoRNA LLC., among others

Exosome Technologies Market – Segmentation

Exosome Type
  • Loaded Cargo
    • Peptide
    • siRNA
    • mRNA
    • Protein
    • Chemical
    • Others
  • Non-cargo
Cell Source
  • HEK293
  • MSCs
  • Platelets
  • Erythrocytes
  • Natural Killer Cells (NKs)
  • Others
Indication
  • Therapeutics
    • Oncology
    • Neurodegenerative Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
    • Cosmetics
    • Others
  • Diagnostics
End User
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Exosome Technologies Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of exosome technologies market?

The global exosome technologies market was worth US$ 31 Mn and is projected to reach a value of US$ 300 Mn by the end of 2031

What is the anticipated CAGR of the exosome technologies market in the forecast period?

Exosome technologies market is anticipated to grow at a CAGR of 8.5% during the forecast period

Which region is expected to project the highest market share in the global exosome technologies market?

North america accounted for a major share of the global exosome technologies market

What are the key driving factors for the growth of the exosome technologies market?

Exosome Technologies Market is driven by increase in awareness about exosome technologies & government initiatives, high incidence rate of chronic diseases and technological advancement

Who are the key players in the global exosome technologies market?

Key players in the global exosome technologies market include Aegle Therapeutics, Anjarium Biosciences, Aruna Biomedical, Carmine Therapeutics, Evox Therapeutics, Exosome Diagnostics, Inc., ExonanoRNA LLC.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Exosome Technologies Market

4. Market Overview

    4.1. Introduction

        4.1.1. Exosome Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Exosome Technologies Market Analysis and Forecast, 2015–2031

5. Key Insights

    5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.3. Pipeline Analysis 

    5.4. Technological Advancement 

    5.5. Licensing deals (IP portfolio/patent/status of - Codiak, Ciloa SAS, Evox, and ExonanoRNA LLC)

6. Global Exosome Technologies Market Analysis and Forecast, by Exosome Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Exosome Type, 2015–2031

        6.3.1. Loaded Cargo

            6.3.1.1. Peptide 

            6.3.1.2. siRNA

            6.3.1.3. mRNA

            6.3.1.4. miRNA

            6.3.1.5. Protein

            6.3.1.6. Chemical 

            6.3.1.7. Others 

        6.3.2. Non-cargo

    6.4. Market Attractiveness Analysis, by Exosome Type 

7. Global Exosome Technologies Market Analysis and Forecast, by Cell Source

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Market Value Forecast, by Cell Source, 2015–2031

        7.2.1. HEK293 

        7.2.2. MSCs

        7.2.3. Platelets 

        7.2.4. Erythrocytes 

        7.2.5. Natural Killer Cells (NKs) 

        7.2.6. Others 

    7.3. Market Attractiveness Analysis, by Cell Source

8. Global Exosome Technologies Market Analysis and Forecast, by Indication

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Market Value Forecast, by Indication, 2015–2031

        8.2.1. Therapeutics

            8.2.1.1. Oncology 

            8.2.1.2. Neurodegenerative Diseases

            8.2.1.3. Cardiovascular Diseases

            8.2.1.4. Infectious Diseases

            8.2.1.5. Cosmetics

            8.2.1.6. Others 

        8.2.2. Diagnostics 

    8.3. Market Attractiveness Analysis, by Indication

9. Global Exosome Technologies Market Analysis and Forecast, by End-user

    9.1. Introduction & Definition

        9.1.1. Key Findings / Developments

    9.2. Market Value Forecast, by End-user, 2015–2031

        9.2.1. Health Care Providers

        9.2.2. Pharmaceutical & Biotechnology Companies 

        9.2.3. Others

    9.3. Market Attractiveness Analysis, by End-user

10. Global Exosome Technologies Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. Market Attractiveness Analysis, by Country/Region

11. North America Exosome Technologies Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Exosome Type, 2015–2031

        11.2.1. Loaded Cargo

            11.2.1.1. Peptide 

            11.2.1.2. siRNA

            11.2.1.3. mRNA

            11.2.1.4. miRNA

            11.2.1.5. Protein

            11.2.1.6. Chemical 

            11.2.1.7. Others 

        11.2.2. Non-cargo

    11.3. Market Value Forecast, by Cell Source, 2015–2031

        11.3.1. HEK293 

        11.3.2. MSCs

        11.3.3. Platelets 

        11.3.4. Erythrocytes 

        11.3.5. Natural Killer Cells (NKs) 

        11.3.6. Others 

    11.4. Market Value Forecast, by Indication, 2015–2031

        11.4.1. Therapeutics

            11.4.1.1. Oncology 

            11.4.1.2. Neurodegenerative Diseases

            11.4.1.3. Cardiovascular Diseases

            11.4.1.4. Infectious Diseases

            11.4.1.5. Cosmetics

            11.4.1.6. Others 

        11.4.2. Diagnostics 

    11.5. Market Value Forecast, by End-user, 2015–2031

        11.5.1. Health Care Providers

        11.5.2. Pharmaceutical & Biotechnology Companies 

        11.5.3. Others

    11.6. Market Value Forecast, by Country, 2015–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis 

        11.7.1. By Exosome Type 

        11.7.2. By Cell Source

        11.7.3. By Indication

        11.7.4. By End-user

        11.7.5. By Country

12. Europe Exosome Technologies Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Exosome Type, 2015–2031

        12.2.1. Loaded Cargo

            12.2.1.1. Peptide 

            12.2.1.2. siRNA

            12.2.1.3.  mRNA

            12.2.1.4.  miRNA

            12.2.1.5. Protein

            12.2.1.6. Chemical 

            12.2.1.7. Others 

        12.2.2. Non-cargo

    12.3. Market Value Forecast, by Cell Source, 2015–2031

        12.3.1. HEK293 

        12.3.2. MSCs

        12.3.3. Platelets 

        12.3.4. Erythrocytes 

        12.3.5. Natural Killer Cells (NKs) 

        12.3.6. Others 

    12.4. Market Value Forecast, by Indication, 2015–2031

        12.4.1. Therapeutics

            12.4.1.1. Oncology 

            12.4.1.2. Neurodegenerative Diseases

            12.4.1.3. Cardiovascular Diseases

            12.4.1.4. Infectious Diseases

            12.4.1.5. Cosmetics

            12.4.1.6. Others 

        12.4.2. Diagnostics 

    12.5. Market Value Forecast, by End-user, 2015–2031

        12.5.1. Health Care Providers

        12.5.2. Pharmaceutical & Biotechnology Companies 

        12.5.3. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2015–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis 

        12.7.1. By Exosome Type 

        12.7.2. By Cell Source

        12.7.3. By Indication

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Exosome Technologies Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Exosome Type, 2015–2031

        13.2.1. Loaded Cargo

            13.2.1.1. Peptide 

            13.2.1.2. siRNA

            13.2.1.3. mRNA

            13.2.1.4.  miRNA

            13.2.1.5. Protein

            13.2.1.6. Chemical 

            13.2.1.7. Others 

        13.2.2. Non-cargo

    13.3. Market Value Forecast, by Cell Source, 2015–2031

        13.3.1. HEK293 

        13.3.2. MSCs

        13.3.3. Platelets 

        13.3.4. Erythrocytes 

        13.3.5. Natural Killer Cells (NKs) 

        13.3.6. Others 

    13.4. Market Value Forecast, by Indication, 2015–2031

        13.4.1. Therapeutics

            13.4.1.1. Oncology 

            13.4.1.2. Neurodegenerative Diseases

            13.4.1.3. Cardiovascular Diseases

            13.4.1.4. Infectious Diseases

            13.4.1.5. Cosmetics

            13.4.1.6. Others 

        13.4.2. Diagnostics 

    13.5. Market Value Forecast, by End-user, 2015–2031

        13.5.1. Health Care Providers

        13.5.2. Pharmaceutical & Biotechnology Companies 

        13.5.3. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2015–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis 

        13.7.1. By Exosome Type 

        13.7.2. By Cell Source

        13.7.3. By Indication

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Latin America Exosome Technologies Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Exosome Type, 2015–2031

        14.2.1. Loaded Cargo

            14.2.1.1. Peptide 

            14.2.1.2. siRNA

            14.2.1.3. mRNA

            14.2.1.4. miRNA

            14.2.1.5. Protein

            14.2.1.6. Chemical 

            14.2.1.7. Others 

        14.2.2. Non-cargo

    14.3. Market Value Forecast, by Cell Source, 2015–2031

        14.3.1. HEK293 

        14.3.2. MSCs

        14.3.3. Platelets 

        14.3.4. Erythrocytes 

        14.3.5. Natural Killer Cells (NKs) 

        14.3.6. Others 

    14.4. Market Value Forecast, by Indication, 2015–2031

        14.4.1. Therapeutics

            14.4.1.1. Oncology 

            14.4.1.2. Neurodegenerative Diseases

            14.4.1.3. Cardiovascular Diseases

            14.4.1.4. Infectious Diseases

            14.4.1.5. Cosmetics

            14.4.1.6. Others 

        14.4.2. Diagnostics 

    14.5. Market Value Forecast, by End-user, 2015–2031

        14.5.1. Health Care Providers

        14.5.2. Pharmaceutical & Biotechnology Companies 

        14.5.3. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2015–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis 

        14.7.1. By Exosome Type 

        14.7.2. By Cell Source

        14.7.3. By Indication

        14.7.4. By End-user

        14.7.5. By Country/Sub-region

15. Middle East & Africa Exosome Technologies Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Exosome Type, 2015–2031

        15.2.1. Loaded Cargo

            15.2.1.1. Peptide 

            15.2.1.2. siRNA

            15.2.1.3. mRNA

            15.2.1.4. miRNA

            15.2.1.5. Protein

            15.2.1.6. Chemical 

            15.2.1.7. Others 

        15.2.2. Non-cargo

    15.3. Market Value Forecast, by Cell Source, 2015–2031

        15.3.1. HEK293 

        15.3.2. MSCs

        15.3.3. Platelets 

        15.3.4. Erythrocytes 

        15.3.5. Natural Killer Cells (NKs) 

        15.3.6. Others 

    15.4. Market Value Forecast, by Indication, 2015–2031

        15.4.1. Therapeutics

            15.4.1.1. Oncology 

            15.4.1.2. Neurodegenerative Diseases

            15.4.1.3. Cardiovascular Diseases

            15.4.1.4. Infectious Diseases

            15.4.1.5. Cosmetics

            15.4.1.6. Others 

        15.4.2. Diagnostics 

    15.5. Market Value Forecast, by End-user, 2015–2031

        15.5.1. Health Care Providers

        15.5.2. Pharmaceutical & Biotechnology Companies 

        15.5.3. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2015–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis 

        15.7.1. By Exosome Type 

        15.7.2. By Cell Source

        15.7.3. By Indication

        15.7.4. By End-user

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by tier and size of companies)

    16.2. Market Share Analysis/Ranking, by Company, 2020

    16.3. Company Profiles

        16.3.1. Aegle Therapeutics 

            16.3.1.1. Company Overview

            16.3.1.2. Company Financials

            16.3.1.3. Growth Strategies

            16.3.1.4. SWOT Analysis

        16.3.2. Anjarium Biosciences 

            16.3.2.1. Company Overview

            16.3.2.2. Company Financials

            16.3.2.3. Growth Strategies

            16.3.2.4. SWOT Analysis

        16.3.3. Aruna Biomedical 

            16.3.3.1. Company Overview

            16.3.3.2. Company Financials

            16.3.3.3. Growth Strategies

            16.3.3.4. SWOT Analysis

        16.3.4. Carmine Therapeutics 

            16.3.4.1. Company Overview

            16.3.4.2. Company Financials

            16.3.4.3. Growth Strategies

            16.3.4.4. SWOT Analysis

        16.3.5. Ciloa SAS 

            16.3.5.1. Company Overview

            16.3.5.2. Company Financials

            16.3.5.3. Growth Strategies

            16.3.5.4. SWOT Analysis

        16.3.6. Codiak BioSciences 

            16.3.6.1. Company Overview

            16.3.6.2. Company Financials

            16.3.6.3. Growth Strategies

            16.3.6.4. SWOT Analysis

        16.3.7. Creative Biolabs 

            16.3.7.1. Company Overview

            16.3.7.2. Company Financials

            16.3.7.3. Growth Strategies

            16.3.7.4. SWOT Analysis

        16.3.8. Danaher Corporation (Beckman Coulter) 

            16.3.8.1. Company Overview

            16.3.8.2. Company Financials

            16.3.8.3. Growth Strategies

            16.3.8.4. SWOT Analysis

        16.3.9. Direct Biologics 

            16.3.9.1. Company Overview

            16.3.9.2. Company Financials

            16.3.9.3. Growth Strategies

            16.3.9.4. SWOT Analysis

        16.3.10. Evercyte

            16.3.10.1. Company Overview

            16.3.10.2. Company Financials

            16.3.10.3. Growth Strategies

            16.3.10.4. SWOT Analysis

        16.3.11. Evox Therapeutics 

            16.3.11.1. Company Overview

            16.3.11.2. Company Financials

            16.3.11.3. Growth Strategies

            16.3.11.4. SWOT Analysis

        16.3.12. ExoCan Healthcare Technologies Pvt. Ltd. 

            16.3.12.1. Company Overview

            16.3.12.2. Company Financials

            16.3.12.3. Growth Strategies

            16.3.12.4. SWOT Analysis

        16.3.13. ExoCoBio

            16.3.13.1. Company Overview

            16.3.13.2. Company Financials

            16.3.13.3. Growth Strategies

            16.3.13.4. SWOT Analysis

        16.3.14. ExonanoRNA LLC 

            16.3.14.1. Company Overview

            16.3.14.2. Company Financials

            16.3.14.3. Growth Strategies

            16.3.14.4. SWOT Analysis

        16.3.15. Exopharm

            16.3.15.1. Company Overview

            16.3.15.2. Company Financials

            16.3.15.3. Growth Strategies

            16.3.15.4. SWOT Analysis

        16.3.16. Exosome Diagnostics, Inc. (BIO-TECHNE CORPORATION) 

            16.3.16.1. Company Overview

            16.3.16.2. Company Financials

            16.3.16.3. Growth Strategies

            16.3.16.4. SWOT Analysis

        16.3.17. Fujifilm

            16.3.17.1. Company Overview

            16.3.17.2. Company Financials

            16.3.17.3. Growth Strategies

            16.3.17.4. SWOT Analysis

        16.3.18. ILIAS Biologics, Inc. 

            16.3.18.1. Company Overview

            16.3.18.2. Company Financials

            16.3.18.3. Growth Strategies

            16.3.18.4. SWOT Analysis

        16.3.19. Illumina, Inc. 

            16.3.19.1. Company Overview

            16.3.19.2. Company Financials

            16.3.19.3. Growth Strategies

            16.3.19.4. SWOT Analysis

        16.3.20. Invitrix Therapeutics

            16.3.20.1. Company Overview

            16.3.20.2. Company Financials

            16.3.20.3. Growth Strategies

            16.3.20.4. SWOT Analysis 

        16.3.21. XOStem, Inc. 

            16.3.21.1. Company Overview

            16.3.21.2. Company Financials

            16.3.21.3. Growth Strategies

            16.3.21.4. SWOT Analysis

        16.3.22. VivaZome Therapeutics Pty Ltd. 

            16.3.22.1. Company Overview

            16.3.22.2. Company Financials

            16.3.22.3. Growth Strategies

            16.3.22.4. SWOT Analysis

        16.3.23. Thermo Fisher Scientific, Inc. 

            16.3.23.1. Company Overview

            16.3.23.2. Company Financials

            16.3.23.3. Growth Strategies

            16.3.23.4. SWOT Analysis

        16.3.24. Organicell

            16.3.24.1. Company Overview

            16.3.24.2. Company Financials

            16.3.24.3. Growth Strategies

            16.3.24.4. SWOT Analysis

        16.3.25. OmniSpirant Ltd. 

            16.3.25.1. Company Overview

            16.3.25.2. Company Financials

            16.3.25.3. Growth Strategies

            16.3.25.4. SWOT Analysis

        16.3.26. Novadip Biosciences 

            16.3.26.1. Company Overview

            16.3.26.2. Company Financials

            16.3.26.3. Growth Strategies

            16.3.26.4. SWOT Analysis

        16.3.27. MDimune Inc. 

            16.3.27.1. Company Overview

            16.3.27.2. Company Financials

            16.3.27.3. Growth Strategies

            16.3.27.4. SWOT Analysis

        16.3.28. Lonza

            16.3.28.1. Company Overview

            16.3.28.2. Company Financials

            16.3.28.3. Growth Strategies

            16.3.28.4. SWOT Analysis

        16.3.29. Kimera Labs 

            16.3.29.1. Company Overview

            16.3.29.2. Company Financials

            16.3.29.3. Growth Strategies

            16.3.29.4. SWOT Analysis

        16.3.30. QIAGEN

            16.3.30.1. Company Overview

            16.3.30.2. Company Financials

            16.3.30.3. Growth Strategies

            16.3.30.4. SWOT Analysis

        16.3.31. Takara Bio, Inc. 

            16.3.31.1. Company Overview

            16.3.31.2. Company Financials

            16.3.31.3. Growth Strategies

            16.3.31.4. SWOT Analysis

        16.3.32. Tavec Pharma

            16.3.32.1. Company Overview

            16.3.32.2. Company Financials

            16.3.32.3. Growth Strategies

            16.3.32.4. SWOT Analysis

List of Tables

Table 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015–2031

Table 02: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015–2031

Table 03: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015–2031

Table 04: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015–2031

Table 05: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015–2031

Table 06: Global Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015–2031

Table 07: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Region, 2015–2031

Table 08: North America Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country, 2015–2031

Table 09: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015–2031

Table 10: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015–2031

Table 11: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015–2031

Table 12: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015–2031

Table 13: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015–2031

Table 14: North America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015–2031

Table 15: Europe Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015–2031

Table 16: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015–2031

Table 17: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015–2031

Table 18: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015–2031

Table 19: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015–2031

Table 20: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015–2031

Table 21: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015–2031

Table 22: Asia Pacific Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015–2031

Table 23: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015–2031

Table 24: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015–2031

Table 25: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015–2031

Table 26: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015–2031

Table 27: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015–2031

Table 28: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015–2031

Table 29: Latin America Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015–2031

Table 30: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015–2031

Table 31: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015–2031

Table 32: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015–2031

Table 33: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015–2031

Table 34: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015–2031

Table 35: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015–2031

Table 36: Middle East & Africa Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015–2031

Table 37: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015–2031

Table 38: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015–2031

Table 39: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015–2031

Table 40: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015–2031

Table 41: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015–2031

Table 42: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015–2031

List of Figures

Figure 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, 2015–2031

Figure 02: Global Exosome Technologies Market Value Share, by Exosome Type, 2020

Figure 03: Global Exosome Technologies Market Value Share, by Cell Source, 2020

Figure 04: Global Exosome Technologies Market Value Share, by Indication, 2020

Figure 05: Global Exosome Technologies Market Value Share, by End-user, 2020

Figure 06: Global Exosome Technologies Market Value Share, by Region, 2020

Figure 07: Global Exosome Technologies Market Value Share Analysis, by Exosome Type, 2020 and 2031

Figure 08: Global Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021–2031

Figure 09: Global Exosome Technologies Market Revenue (US$ Mn), by Loaded Cargo, 2015–2031

Figure 10: Global Exosome Technologies Market Revenue (US$ Mn), by Non-cargo, 2015–2031

Figure 11: Global Exosome Technologies Market Value Share Analysis, by Cell Source, 2020 and 2031

Figure 12: Global Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021–2031

Figure 13: Global Exosome Technologies Market Revenue (US$ Mn), by HEK293, 2015–2031

Figure 14: Global Exosome Technologies Market Revenue (US$ Mn), by MSCs, 2015–2031

Figure 15: Global Exosome Technologies Market Revenue (US$ Mn), by Platelets, 2015–2031

Figure 16: Global Exosome Technologies Market Revenue (US$ Mn), by Erythrocytes, 2015–2031

Figure 17: Global Exosome Technologies Market Revenue (US$ Mn), by Natural Killer Cells (NKs), 2015–2031

Figure 18: Global Exosome Technologies Market Revenue (US$ Mn), by Others, 2015–2031

Figure 19: Global Exosome Technologies Market Value Share Analysis, by Indication, 2020 and 2031

Figure 20: Global Exosome Technologies Market Attractiveness Analysis, by Indication, 2021–2031

Figure 21: Global Exosome Technologies Market Revenue (US$ Mn), by Therapeutics, 2015–2031

Figure 22: Global Exosome Technologies Market Revenue (US$ Mn), by Diagnostics, 2015–2031

Figure 23: Global Exosome Technologies Market Value Share Analysis, by End-user, 2020 and 2031

Figure 24: Global Exosome Technologies Market Attractiveness Analysis, by End-user, 2021–2031

Figure 25: Global Exosome Technologies Market Revenue (US$ Mn), by Health Care Providers, 2015–2031

Figure 26: Global Exosome Technologies Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2015–2031

Figure 27: Global Exosome Technologies Market Revenue (US$ Mn), by Others, 2015–2031

Figure 28: Global Exosome Technologies Market Value Share Analysis, by Region, 2020 and 2031

Figure 29: Global Exosome Technologies Market Attractiveness Analysis, by Region, 2021–2031

Figure 30: North America Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (percentage) Projection, 2015–2031

Figure 31: North America Exosome Technologies Market Value Share (%), by Country, 2020 and 2031

Figure 32: North America Exosome Technologies Market Attractiveness Analysis, by Country, 2021–2031

Figure 33: North America Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031

Figure 34: North America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021–2031

Figure 35: North America Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031

Figure 36: North America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021–2031

Figure 37: North America Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031

Figure 38: North America Exosome Technologies Market Attractiveness Analysis, by Indication, 2021–2031

Figure 39: North America Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031

Figure 40: North America Exosome Technologies Market Attractiveness Analysis, by End-user, 2021–2031

Figure 41: Europe Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2031

Figure 42: Europe Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 43: Europe Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 44: Europe Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031

Figure 45: Europe Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021–2031

Figure 46: Europe Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031

Figure 47: Europe Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021–2031

Figure 48: Europe Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031

Figure 49: Europe Exosome Technologies Market Attractiveness Analysis, by Indication, 2021–2031

Figure 50: Europe Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031

Figure 51: Europe Exosome Technologies Market Attractiveness Analysis, by End-user, 2021–2031

Figure 52: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2031

Figure 53: Asia Pacific Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 54: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 55: Asia Pacific Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031

Figure 56: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021–2031

Figure 57: Asia Pacific Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031

Figure 58: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021–2031

Figure 59: Asia Pacific Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031

Figure 60: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Indication, 2021–2031

Figure 61: Asia Pacific Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031

Figure 62: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by End-user, 2021–2031

Figure 63: Latin America Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2031

Figure 64: Latin America Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 65: Latin America Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 66: Latin America Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031

Figure 67: Latin America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021–2031

Figure 68: Latin America Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031

Figure 69: Latin America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021–2031

Figure 70: Latin America Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031

Figure 71: Latin America Exosome Technologies Market Attractiveness Analysis, by Indication, 2021–2031

Figure 72: Latin America Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031

Figure 73: Latin America Exosome Technologies Market Attractiveness Analysis, by End-user, 2021–2031

Figure 74: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2031

Figure 75: Middle East & Africa Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 76: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 77: Middle East & Africa Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031

Figure 78: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021–2031

Figure 79: Middle East & Africa Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031

Figure 80: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021–2031

Figure 81: Middle East & Africa Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031

Figure 82: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Indication, 2021–2031

Figure 83: Middle East & Africa Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031

Figure 84: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by End-user, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

219

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved